ATE321846T1 - Verwendung eines modifizierten protein-c - Google Patents

Verwendung eines modifizierten protein-c

Info

Publication number
ATE321846T1
ATE321846T1 AT97946594T AT97946594T ATE321846T1 AT E321846 T1 ATE321846 T1 AT E321846T1 AT 97946594 T AT97946594 T AT 97946594T AT 97946594 T AT97946594 T AT 97946594T AT E321846 T1 ATE321846 T1 AT E321846T1
Authority
AT
Austria
Prior art keywords
protein
region
cofactors
modified
gla
Prior art date
Application number
AT97946594T
Other languages
English (en)
Inventor
Charles T Esmon
Mikhail Smirnov
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/745,254 external-priority patent/US5837843A/en
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE321846T1 publication Critical patent/ATE321846T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97946594T 1996-11-08 1997-11-07 Verwendung eines modifizierten protein-c ATE321846T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/745,254 US5837843A (en) 1996-11-08 1996-11-08 Modified protein C
US5376897P 1997-07-25 1997-07-25

Publications (1)

Publication Number Publication Date
ATE321846T1 true ATE321846T1 (de) 2006-04-15

Family

ID=26732221

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946594T ATE321846T1 (de) 1996-11-08 1997-11-07 Verwendung eines modifizierten protein-c

Country Status (9)

Country Link
US (1) US5847085A (de)
EP (1) EP0946715B1 (de)
JP (1) JP2001523949A (de)
AT (1) ATE321846T1 (de)
AU (1) AU730133B2 (de)
CA (1) CA2271232C (de)
DE (1) DE69735597T2 (de)
ES (1) ES2265159T3 (de)
WO (1) WO1998020118A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2002542832A (ja) * 1999-04-30 2002-12-17 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
CA2391651A1 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
AU2001232736A1 (en) 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU1038802A (en) * 2000-10-18 2002-04-29 Maxygen Aps Protein c or activated protein c-like molecules
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
JP4472526B2 (ja) * 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
EP2085470B1 (de) * 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII oder FVIIa Varianten
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
US20130071375A1 (en) * 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
WO1988003926A1 (en) * 1986-11-17 1988-06-02 New England Medical Center Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins
EP0296413A2 (de) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrides Protein C und Verfahren zur Herstellung
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins

Also Published As

Publication number Publication date
DE69735597D1 (de) 2006-05-18
CA2271232C (en) 2005-02-22
US5847085A (en) 1998-12-08
AU730133B2 (en) 2001-02-22
EP0946715B1 (de) 2006-03-29
AU5173398A (en) 1998-05-29
ES2265159T3 (es) 2007-02-01
CA2271232A1 (en) 1998-05-14
JP2001523949A (ja) 2001-11-27
WO1998020118A1 (en) 1998-05-14
DE69735597T2 (de) 2006-12-21
EP0946715A1 (de) 1999-10-06

Similar Documents

Publication Publication Date Title
DE69735597D1 (de) Verwendung eines modifizierten protein-c
Curnutte et al. Reciprocal interactions between protein kinase C and components of the NADPH oxidase complex may regulate superoxide production by neutrophils stimulated with a phorbol ester.
Chapple et al. Glutathione in gingival crevicular fluid and its relation to local antioxidant capacity in periodontal health and disease
Truglia et al. Purification and characterization of a calcium dependent sulfhydryl protease from human platelets
Selak et al. Cathepsin G is a strong platelet agonist released by neutrophils
Liotta et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane
BRECKENRIDGE et al. Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: with notes on an assay for antihemophilic factor
Khan et al. Exposure of cryptic domains in the α1-chain of laminin-1 by elastase stimulates macrophages urokinase and matrix metalloproteinase-9 expression
Boneu et al. Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome
Pontremoli et al. Identification of an endogenous activator of calpain in rat skeletal muscle
Falcone et al. Stimulation of macrophage urokinase expression by polyanions is protein kinase C-dependent and requires protein and RNA synthesis.
Wittig et al. Endothelial-dependent S-Sulfhydration of tissue factor pathway inhibitor regulates blood coagulation
El‐Ghmati et al. Haptoglobin interacts with the human mast cell line HMC‐1 and inhibits its spontaneous proliferation
Stasek et al. The role of protein kinase C in α-thrombin-mediated endothelial cell activation
De Cristofaro et al. Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro-and anticoagulant pathways in healthy subjects
Chasse et al. An abnormal plasma antithrombin with no apparent affinity for heparin
Neill et al. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma
Trifiletti et al. Effects of medium-term antihypertensive therapy on haemostatic parameters in patients with essential hypertension
Harper et al. PAR‐1‐dependent pp60src activation is dependent on protein kinase C and increased [Ca2+] i: evidence that pp60src does not regulate PAR‐1‐dependent Ca2+ entry in human platelets
Åberg et al. Dopamine-β-hydroxylase in human lymph
Bertina et al. Inhibitor-neutralisation assay and electro-immuno assay of human factor IX (Christmas factor)
Rock et al. ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma
Daly et al. Analysis of antithrombin III microheterogeneity by isoelectric focusing in polyacrylamide gels and immunoblotting
ATE278950T1 (de) Verwendung von annexinen als lupus antikoagulans kontrolle oder standard in gerinnungstesten
Haanen et al. Contact activation of Hageman factor and the interaction of Hageman factor and plasma thromboplastin antecedent

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties